This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: I67.5 (Moyamoya disease) | Special Copayment Reduction: V128 (rare disease) |
| B. Synonyms | Not applicable |
| C. Adult onset | Likelihood of first onset in adulthood: high — Moyamoya disease has two peaks of onset, in childhood (age 5–10) and adulthood (30s–40s, especially women). Unlike in children, adult-onset disease more often takes the form of hemorrhagic stroke (intracerebral hemorrhage, intraventricular hemorrhage) than ischemic stroke, so the clinical picture differs. |
| 1. History | First described by Takeuchi and Shimizu in Japan in 1957 → named 'moyamoya' by Suzuki and Takaku in 1969 → RNF213 gene discovered in 2011. |
| 2. Causes | RNF213 gene (17q25.3) variants (East Asian genetic predisposition). The cause of progressive stenosis of the distal intracranial internal carotid artery, middle cerebral artery, and anterior cerebral artery is unknown. |
| 3. Genetics | The RNF213 p.R4810K variant is carried by about 80% of East Asian moyamoya disease patients. Autosomal dominant tendency, incomplete penetrance. Familial occurrence about 10–15%. |
| 4. General epidemiology | Prevalence is markedly higher in East Asia (Japan, Korea, China). Prevalence in Korea about 1.8–2.3 per 100,000 population. Female predominance (F:M = about 1.5–2:1). |
| 5. Pathophysiology | Intimal proliferation and smooth muscle cell abnormalities of the distal internal carotid artery → gradual luminal stenosis and occlusion → development of collateral vessels (moyamoya vessels) → ischemia or hemorrhage. |
| 6. Symptoms | Children: TIA and ischemic stroke (worsened by crying or hyperventilation). Adults: hemorrhagic stroke (headache, impaired consciousness). Headache, cognitive decline, seizures. Hyperventilation-related symptoms are characteristic. |
| 7. Signs | Hemiplegia, speech impairment, visual field abnormalities. MRA shows bilateral distal internal carotid artery stenosis/occlusion + moyamoya vessels. Hypoperfusion on cerebral blood flow studies. |
| 8. Screening | MRA screening of first-degree relatives with a family history. RNF213 genetic testing. MRA is essential in children with recurrent TIA or stroke. |
| 9. Diagnosis | Brain MRI/MRA (or CT/CTA). Cerebral angiography (confirmation). SPECT/PET cerebral blood flow assessment. Suzuki staging (I–VI). |
| 10. Treatment | Surgical revascularization (direct bypass: STA-MCA anastomosis; indirect bypass: EDAS, EMS, EMAS). Antiplatelet agents (aspirin). Acute-phase treatment when ischemia or hemorrhage occurs. |
| 11. Prognosis | Stroke recurrence decreases markedly after surgical revascularization. Without surgery, annual recurrence about 7–10%. Prognosis in children better than in adults. Risk of cognitive impairment with bilateral lesions. |
| 12. Prevention | Prevention of stroke recurrence with early revascularization. Family screening MRA. Avoidance of dehydration and hyperventilation. Antiplatelet therapy. |
| 13. References | Suzuki J, Takaku A. Cerebrovascular "moyamoya" disease. Arch Neurol. 1969 … and 9 other papers |
The historical description of Moyamoya disease (もやもや disease) began with Takeuchi and Shimizu in Japan in 1957. They reported patients showing occlusion of the internal carotid artery and distinctive collateral vessel development. Subsequently, as similar case reports followed in Japan in the 1960s, the concept of an independent disease took shape.
In 1969, Jiro Suzuki and Akira Takaku observed on cerebral angiography the characteristic finding of numerous fine collateral vessels forming at the skull base like rising mist, together with occlusion of the distal internal carotid artery, and coined the term because the image evoked the Japanese word 'もやもや (moyamoya)', meaning smoke or haze. With the publication of this paper in Archives of Neurology, the name 'moyamoya disease' came into international use.
In the 1970s–80s, surgical revascularization was introduced and treatment advanced. Yamashita, Fujii, Matsushima, and others demonstrated the efficacy of indirect bypass (EDAS, encephaloduroarteriosynangiosis), and direct bypass (STA-MCA anastomosis) also became the standard in adults. Official epidemiological studies began in Japan in the 1970s, confirming the East Asian predominance, and in Korea case reports and systematic research also proceeded from this period.
In 2011, the Yamaguchi group in Japan discovered through a genome-wide association study (GWAS) that the p.R4810K variant (c.14429G>A) of the RNF213 gene (17q25.3) is strongly associated with East Asian moyamoya disease. This variant is found in about 80% of East Asian moyamoya disease patients and was confirmed as a strong genetic susceptibility factor. Research on the function of RNF213 (E3 ubiquitin ligase, regulation of vascular development) has since been active, opening a new chapter in understanding the molecular pathogenesis of moyamoya disease.
Korea is currently one of the world's leading countries in moyamoya disease research and surgical treatment, and large cohort studies and surgical outcomes centered on Seoul National University Hospital are receiving international attention. Revised Korean moyamoya disease clinical practice guidelines were published in 2021.
The cause of moyamoya disease has not yet been fully elucidated. The core pathology is gradual stenosis and occlusion of the distal intracranial internal carotid artery (ICA) and the proximal anterior cerebral artery (ACA) and middle cerebral artery (MCA), in response to which numerous fine collateral vessels (moyamoya vessels) develop at the skull base.
Histopathologically, the stenotic segments show fibrous thickening of the intima, abnormal proliferation and migration of smooth muscle cells, disruption of the internal elastic lamina, and thinning of the media. Migration and proliferation of smooth muscle cells from the arterial media into the intima causes the stenosis, and vascular endothelial cell dysfunction, overexpression of growth factors (bFGF, HGF, VEGF, TGF-β1), and abnormalities of connective tissue metabolism have been proposed to be involved in this process.
Association with the RNF213 gene: The p.R4810K variant of the RNF213 gene is the most important genetic susceptibility factor for East Asian moyamoya disease. The RNF213 protein is an E3 ubiquitin ligase with an AAA+ ATPase domain and is known to be involved in vascular development and inflammatory responses. Abnormal angiogenesis was observed in RNF213-deficient mouse models, but spontaneous stenotic lesions resembling moyamoya disease were not reproduced, so it is understood as a genetic susceptibility factor rather than a sole cause.
When an underlying disease accompanies moyamoya disease, it is distinguished as 'moyamoya syndrome'. A moyamoya pattern appears in Down syndrome, neurofibromatosis type 1 (NF1), sickle cell anemia, vascular injury after radiation therapy, autoimmune thyroid disease, Turner syndrome, and others. Unlike moyamoya disease, these require concurrent treatment of the underlying disease.
The most important genetic factor in moyamoya disease is the single nucleotide polymorphism p.R4810K (rs112735431) of the RNF213 gene (ring finger protein 213, 17q25.3). This variant is found in about 70–95% of moyamoya disease patients in East Asia, including Korea, Japan, and China (varying somewhat between studies), and the carrier rate in the general East Asian population is also about 1.5–2%. This suggests that the penetrance of moyamoya disease is low (the proportion of RNF213 variant carriers who develop moyamoya disease is only a few percent) and that additional genetic or environmental factors are needed for disease onset.
Besides the RNF213 p.R4810K variant, numerous rare variants such as p.A4399T, p.E4950D, and p.R4162Q are associated with moyamoya disease. In Caucasian (non-East Asian) patients, variants in other genes besides RNF213 are presumed to be involved. Genome-wide studies have also reported that ACTA2 (smooth muscle alpha-actin gene) mutations are associated with some cases of familial moyamoya syndrome.
Familial moyamoya disease accounts for about 10–15% of the total and occurs among siblings or between parents and children. The inheritance pattern tends toward autosomal dominant with incomplete penetrance, but it is understood as the combined action of polygenic predisposition and environmental factors. Screening of first-degree relatives of patients with a family history through MRA or RNF213 genetic testing is recommended.
Moyamoya disease shows regional specificity, with markedly higher prevalence in East Asia (Japan, Korea, China). Prevalence is reported as about 10–11 per 100,000 population in Japan and about 1.8–2.3 in Korea, but with recent improvements in diagnostic technology and analysis of health insurance claims data, the actual prevalence is estimated to be higher. It is very rare in Western countries, at less than 0.1 per 100,000 population.
Age of onset has two distinct peaks. The first peak is in childhood (age 5–10), when ischemic stroke or transient ischemic attack (TIA) is the main presentation. The second peak is in adulthood (30s–40s), particularly prominent in women, with a higher proportion of hemorrhagic than ischemic stroke. By sex, women are affected about 1.5–2 times more than men, which supports the hypothesis that sex hormones influence the progression of vascular lesions.
In a study analyzing Korean health insurance data, the annual incidence of moyamoya disease is reported as about 0.5–1 per 100,000 population, which is lower than in Japan and markedly higher than in Western countries. In Korea, moyamoya disease is a rare disease eligible for Special Copayment Reduction (V128) registration. The proportion of familial cases in Korea is reported as about 12–15%, similar to Japan (about 10%). Moyamoya syndrome (with an underlying disease) accounts for about 15–20% of the total.
The core of the pathophysiology of moyamoya disease is gradual stenosis and occlusion of the distal intracranial internal carotid artery and the proximal anterior and middle cerebral arteries, with extensive collateral vessel formation in response.
Mechanism of vascular stenosis: Histopathology of the affected vessels shows intimal fibrous thickening, migration and proliferation of medial smooth muscle cells into the intima, and disruption of the internal elastic lamina. This is a distinctive pattern different from atherosclerotic changes (lipid accumulation, inflammatory cell infiltration). It has been proposed that RNF213 protein abnormalities disrupt the ubiquitin-proteasome pathway of vascular endothelial cells, altering vascular smooth muscle cell migration and angiogenic responses. There are also reports that growth factor abnormalities (bFGF, VEGF, HGF, etc.) promote vascular smooth muscle cell proliferation.
Formation of moyamoya vessels: In response to internal carotid artery stenosis and occlusion, the perforating arteries of the skull base (lenticulostriate arteries, thalamoperforating arteries) dilate and proliferate to form moyamoya vessels that supply collateral blood flow. These vessels appear like a hazy puff of smoke on angiography. Moyamoya vessels have thinner, more fragile walls than normal vessels and carry a risk of rupture, and they are the main cause of intracerebral and intraventricular hemorrhage in adults.
Mechanism of ischemia: In children and some adults, ICA stenosis and occlusion reduce anterior cerebral blood flow, causing hypoperfusion especially of the frontal and parietal cortex. A characteristic triggering mechanism in children is that a decrease in PaCO2 from hyperventilation (crying, exercise, fever) constricts the cerebral vessels and worsens ischemia. Recurrent ischemia causes cognitive decline and learning disabilities.
Mechanism of hemorrhage: In adults, rupture of moyamoya vessels (especially periventricular vessels) causes intracerebral or intraventricular hemorrhage. Reduction in hemorrhage risk as revascularization decreases the hemodynamic load on moyamoya vessels is understood to be a major effect of surgery.
The clinical symptoms of moyamoya disease vary with age and the extent of vascular involvement, and show distinctly different patterns in children and adults.
Symptoms in children: The most common initial symptom is transient ischemic attack (TIA) or ischemic stroke. Characteristic in children is that hyperventilation during crying, exercise, or eating hot food triggers TIA or stroke. This is because the decrease in PaCO2 and cerebral vasoconstriction from hyperventilation cause critical ischemia in a brain already in a hypoperfused state. Symptoms include recurrent hemiplegia, speech impairment (aphasia, dysarthria), visual field abnormalities, and sensory abnormalities, varying with the vascular territory involved. Seizures may occur, and cognitive decline, learning disabilities, and headache due to recurrent ischemia are also common.
Symptoms in adults: In adults, hemorrhagic stroke is more common than ischemia. The main presentation is intracerebral hemorrhage or intraventricular hemorrhage due to rupture of moyamoya vessels, with sudden headache, nausea and vomiting, decreased consciousness, hemiplegia, and so on. Ischemic presentations (TIA, cerebral infarction) also occur, and symptoms tend to worsen particularly in women around pregnancy and childbirth. Chronic headache and cognitive decline are also important symptoms in adults.
Symptoms common to children and adults: Headache (often recurrent and migraine-like), cognitive decline, memory impairment. In the natural course, symptoms repeatedly worsen and remit, with an overall progressive course.
The physical signs of moyamoya disease are mainly focal neurological deficits appearing during or after episodes of stroke or TIA.
Neurological signs: Hemiplegia or hemiparesis, hemisensory abnormalities, aphasia (Broca's or Wernicke's aphasia), visual field defects (homonymous hemianopia), dysarthria, and so on are observed during or after ischemic episodes. Permanent neurological deficits may remain after recurrent ischemia, with decline in language and cognitive function being particularly prominent. In children, intellectual decline and learning disabilities sometimes occur after recurrent ischemia. In hemorrhagic presentations, sudden severe headache ('the worst headache of my life'), altered consciousness, vomiting, and meningeal irritation signs appear.
Imaging findings: Brain MRI shows multiple cortical and subcortical infarcts (children) or intracerebral and intraventricular hemorrhage (adults). MRA characteristically shows stenosis and occlusion of the bilateral distal internal carotid arteries and the proximal anterior and middle cerebral arteries, with proliferation of skull-base perforating vessels (moyamoya vessels). Cerebral angiography (DSA) is the gold standard for diagnosis, precisely evaluating the morphology of moyamoya vessels and collateral pathways and determining the Suzuki stage (I–VI). SPECT or PET evaluates areas of cerebral hypoperfusion and cerebrovascular reserve.
Suzuki staging: Based on cerebral angiographic findings, classified as stage I (distal ICA stenosis), stage II (onset of moyamoya vessels), stage III (development of moyamoya vessels), stage IV (maximal moyamoya vessels, beginning disappearance of the anterior and middle cerebral arteries), stage V (reduction of moyamoya vessels, development of extracranial collaterals), and stage VI (disappearance of moyamoya vessels, dependence solely on extracranial collaterals).
General population screening for moyamoya disease is not performed. Systematic screening is recommended in high-risk groups.
Screening of first-degree relatives with a family history: Vascular screening with head MRA is recommended for the siblings and children of patients with confirmed moyamoya disease. Even without symptoms, if distal ICA stenosis is found on MRA, treatment can be started early. Korean and Japanese guidelines recommend performing MRA in first-degree relatives every 5 years or immediately upon onset of symptoms.
RNF213 genetic testing: If the RNF213 p.R4810K variant is confirmed in a family member with confirmed moyamoya disease, targeted genetic testing for that variant can be performed in first-degree relatives. However, because the risk of developing moyamoya disease is low even in RNF213 variant-positive individuals, combining it with MRA is recommended rather than screening with genetic testing alone.
Recurrent TIA and stroke in children: In children with unexplained recurrent TIA or ischemic stroke, especially hyperventilation-related hemiplegia or aphasia, moyamoya disease must be ruled out, and brain MRI/MRA should be performed immediately. Moyamoya disease should also be suspected in recurrent hemiplegia misdiagnosed as epileptic seizures.
Diagnosis of moyamoya disease is based on characteristic imaging findings, and cerebral angiography is the confirmatory method. MRA is used as the noninvasive first-line diagnostic tool.
Brain MRI/MRA: The first-line diagnostic tool. MRI identifies infarcts and hemorrhagic lesions, and MRA identifies stenosis and occlusion of the distal ICA and proximal anterior and middle cerebral arteries and the formation of moyamoya vessels. High-resolution 3D TOF MRA precisely evaluates the degree and distribution of intracranial vascular stenosis. On brain MRI, multiple linear low-signal lesions in the basal ganglia region (ivy sign on FLAIR, superficial leptomeningeal collaterals) are characteristic. In children, the 'ivy sign' is an important supplementary finding suggesting moyamoya disease even when it is not detected on MRA.
Cerebral angiography (DSA, digital subtraction angiography): The gold standard for confirmation and determination of Suzuki stage. Through angiography of the bilateral internal carotid, external carotid, and vertebral arteries, the degree of stenosis, development of moyamoya vessels, and collateral pathways (anterior communicating artery, posterior communicating artery, dural collaterals, extracranial collaterals) are comprehensively evaluated. It is essential for surgical planning.
Cerebral blood flow assessment (SPECT, PET, perfusion MRI): Areas of cerebral hypoperfusion and cerebrovascular reserve (acetazolamide challenge test) are evaluated to determine surgical indications and surgical efficacy. Reduced cerebrovascular reserve (decreased acetazolamide response) is an important indicator for surgery.
Diagnostic criteria: According to the diagnostic criteria of the Research Committee on Moyamoya Disease of the Japanese Ministry of Health and Welfare (revised 2012), moyamoya disease is diagnosed when ① MRA or DSA shows bilateral or unilateral stenosis/occlusion of the distal ICA and the proximal ACA or MCA, ② moyamoya vessels are formed, and ③ causes of moyamoya syndrome such as Down syndrome and NF1 are excluded.
The most effective treatment for moyamoya disease is revascularization surgery. Drug therapy is used for symptom control and as a supplement to surgery.
Direct bypass: STA-MCA anastomosis: Surgery that directly anastomoses a scalp artery (superficial temporal artery, STA) to a cortical branch of the middle cerebral artery (MCA), providing an immediate increase in blood flow. It is preferred in adult moyamoya disease, especially in patients with hemorrhagic presentation and patients with markedly reduced cerebrovascular reserve. Cerebral blood flow improves markedly within several months to 1 year after surgery. Complications include intraoperative ischemia (excessive vasoconstriction) and hyperperfusion syndrome, so caution is required.
Indirect bypass: A method of attaching scalp, dural, and muscle tissue to the brain surface to induce new vessel formation over the long term. Representative procedures: EDAS (encephaloduroarteriosynangiosis, attaching a scalp artery and dura to the brain surface), EMS (encephalomyosynangiosis, attaching the temporalis muscle to the brain), EMAS (EMS + EDAS combined). It is mainly used in children when vessels are too small for direct anastomosis and induces effective neovascularization over the long term.
Combined bypass: A method of performing direct + indirect bypass in the same operation, aiming for maximal revascularization. It is widely used in specialized centers in Korea and Japan.
Antiplatelet therapy: Aspirin is used to prevent thrombus formation. It is especially important in the preoperative and immediate postoperative periods. However, antiplatelet agents themselves do not prevent hemorrhage due to rupture of moyamoya vessels.
Acute-phase treatment: Use of thrombolytics (rt-PA) in acute ischemic stroke is not recommended in moyamoya disease; supportive care and prompt planning of revascularization take priority. In hemorrhagic presentations, blood pressure control, intracranial pressure management, and hematoma evacuation surgery if needed are considered.
The natural course of moyamoya disease is progressive, and without treatment, permanent neurological disability accumulates from recurrent strokes.
Natural course before surgery: The annual recurrence rate of ischemic or hemorrhagic stroke in moyamoya disease patients who have not undergone surgical revascularization is reported as about 7–10%. Children in particular are at high risk of cognitive decline and learning disabilities from recurrent ischemia. In adult hemorrhagic moyamoya disease, the risk of rebleeding is high and the prognosis is poorer.
Prognosis after surgery: The risk of stroke recurrence decreases markedly after surgical revascularization. Large cohort studies have reported that the annual rate of ischemic events after revascularization falls to about 1–2%, and hemorrhagic recurrence also decreases significantly. In children, neurodevelopmental prognosis after surgery is better, and early surgery is important for preserving cognitive function. In adults too, improvement in activities of daily living and reduced stroke risk after surgery have been reported. The surgical success rate (adequate revascularization) is over 95% in specialized centers.
Long-term prognostic factors: Bilateral lesions have a poorer prognosis than unilateral lesions. The degree of neurological deficit at the time of surgery and the extent of infarct lesions determine long-term prognosis. In patients with hemorrhagic presentation, the severity of the initial hemorrhage affects prognosis. Lesion progression and surgical efficacy are monitored with regular brain MRI/MRA follow-up.
Complete primary prevention of moyamoya disease is not possible with current technology. The main preventive strategy lies in preventing stroke recurrence through surgical revascularization after early diagnosis.
Family screening and early surgery: Detecting lesions at the asymptomatic stage through MRA screening of first-degree relatives of moyamoya disease patients and performing early revascularization is the most effective way to prevent stroke itself. Especially in children, surgery is performed immediately upon diagnosis to minimize cognitive damage from recurrent ischemia.
Avoidance of triggering factors: In children, hyperventilation (crying, vigorous exercise) worsens cerebral ischemia, so education of parents and teachers is needed. Inform them of the TIA risk with eating hot food, intense crying, and extreme exercise, and guide them on how to respond. Dehydration raises blood concentration and increases thrombotic risk, so adequate fluid intake is recommended.
Antiplatelet therapy: Aspirin is used to prevent thrombus formation and is especially important in the preoperative period and the early postoperative period. However, in patients with hemorrhagic presentation, antiplatelet agents may increase the risk of bleeding, so individualized use is required.
Regular follow-up: Postoperative patients undergo regular brain MRI/MRA and cerebral blood flow studies (SPECT/PET) to monitor revascularization efficacy and progression in the contralateral vessels. In patients with unilateral moyamoya disease, regular MRA is needed to monitor for the possible development of contralateral vascular lesions (about 20–40%). Neuropsychological assessment and rehabilitation for cognitive decline and psychological problems are included in long-term management.
Suzuki J, Takaku A. Cerebrovascular "moyamoya" disease: disease showing abnormal net-like vessels in base of brain. Arch Neurol. 1969;20(3):288-299. DOI: 10.1001/archneur.1969.00480090076012. PMID: 5775283.
Kamada F, Aoki Y, Narisawa A, et al. A genome-wide association study identifies RNF213 as the first Moyamoya disease gene. J Hum Genet. 2011;56(1):34-40. DOI: 10.1038/jhg.2010.132. PMID: 21048783.
Kim JS. Moyamoya Disease: Epidemiology, Clinical Features, and Diagnosis. J Stroke. 2016;18(1):2-11. DOI: 10.5853/jos.2015.01627. PMID: 26846754.
Research Committee on the Pathology and Treatment of Spontaneous Occlusion of the Circle of Willis (Japan). Guidelines for diagnosis and treatment of moyamoya disease (spontaneous occlusion of the circle of Willis). Neurol Med Chir (Tokyo). 2012;52(5):245-266. DOI: 10.2176/nmc.52.245. PMID: 22870472.
Scott RM, Smith ER. Moyamoya disease and moyamoya syndrome. N Engl J Med. 2009;360(12):1226-1237. DOI: 10.1056/NEJMra0804622. PMID: 19282477.
Miyamoto S, Yoshimoto T, Hashimoto N, et al. Effects of extracranial-intracranial bypass for patients with hemorrhagic moyamoya disease. Stroke. 2014;45(5):1415-1421. DOI: 10.1161/STROKEAHA.113.004386. PMID: 24651274.
Phi JH, Wang KC, Lee JY, Kim SK. Moyamoya Syndrome: A Window of Moyamoya Disease. J Korean Neurosurg Soc. 2015;57(6):408-414. DOI: 10.3340/jkns.2015.57.6.408. PMID: 26113965.
Bang OY, Fujimura M, Kim SK. The Pathophysiology of Moyamoya Disease: An Update. J Stroke. 2016;18(1):12-20. DOI: 10.5853/jos.2015.01760. PMID: 26846755.
Kuriyama S, Kusaka Y, Fujimura M, et al. Prevalence and clinicoepidemiological features of moyamoya disease in Japan: findings from a nationwide epidemiological survey. Stroke. 2008;39(1):42-47. DOI: 10.1161/STROKEAHA.107.490714. PMID: 18048855.
Czabanka M, Pena-Tapia P, Schubert GA, et al. Characterization of direct and indirect cerebrovascular bypass surgery in the treatment of moyamoya disease in a Western patient population. Cerebrovasc Dis. 2011;32(4):361-369. DOI: 10.1159/000330361. PMID: 21893977.